The results of a multicentre double-blind trial are reported in which α-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebut anol (terfenadine, RMI 9918, Triludan®, Teldane®, resp.) and dexchlorpheniramine were compared with placebo in the treatment of allergic rhinitis. Terfenadine and dexchlorpheniramine were found to be equally effective; but terfenadine produced less drowsiness and was effective in a twice daily dosage.
A multicentre controlled trial of terfenadine, dexchlorpheniramine and placebo in allergic rhinitis / G. Melillo,G. D'Amato, C. Zanussi, C. Ortolani, E.A. Pastorello, M. Loy, AM. Di Tucci,F. Locci, GS. Del Giacco, L. Lenzini, P. Sestini, P. Rottoli. - In: ARZNEIMITTEL-FORSCHUNG. - ISSN 0004-4172. - 32:9A(1982), pp. 1202-1203.
A multicentre controlled trial of terfenadine, dexchlorpheniramine and placebo in allergic rhinitis
E.A. Pastorello;
1982
Abstract
The results of a multicentre double-blind trial are reported in which α-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebut anol (terfenadine, RMI 9918, Triludan®, Teldane®, resp.) and dexchlorpheniramine were compared with placebo in the treatment of allergic rhinitis. Terfenadine and dexchlorpheniramine were found to be equally effective; but terfenadine produced less drowsiness and was effective in a twice daily dosage.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
